CIP
NKTR icon

Convergence Investment Partners’s Nektar Therapeutics NKTR Stock Holding History

Convergence Investment Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1
Closed -$2K – 686
2018
Q1 		$2K Buy
+1
New +$1.29K ﹤0.01% 952
2015
Q1 		– Sell
-5,585
Closed -$1.3M – 397
2014
Q4 		$1.3M Buy
+5,585
New +$1.19M 0.17% 200

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Convergence Investment Partners's NKTR Position: Q2 2018 in Review

Convergence Investment Partners sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 1 share — an estimated $2K sold.

Convergence Investment Partners first reported a position in NKTR in Q4 2014 and held it in 2 quarters. The position peaked at $1.3M in Q4 2014. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • Convergence Investment Partners reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Convergence Investment Partners sold 1 Nektar Therapeutics share in Q2 2018, an estimated $2K.
  • Convergence Investment Partners first reported a position in Nektar Therapeutics in Q4 2014 and held it in 2 quarters.
  • Convergence Investment Partners's Nektar Therapeutics position peaked at $1.3M in Q4 2014.
  • 379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Convergence Investment Partners's 13F filing for Q2 2018, filed 7 Aug 2018.